drugset
drugset / Trial / NCT04555148

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

NCT04555148 ↗

Phase 2 Completed 63 enrolled Green Cross Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of 5131A for hospitalized patients of COVID-19.

Timeline

Start
2020-09-19
Primary completion
2021-01-22
Completion
2021-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GC5131 Protein / enzyme biologic — —

Indications

COVID-19